SNDL Future Growth
Future criteria checks 1/6
SNDL is forecast to grow earnings and revenue by 111.6% and 5.5% per annum respectively while EPS is expected to grow by 114.8% per annum.
Key information
111.6%
Earnings growth rate
114.8%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | 5.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 05 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,050 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 966 | -14 | 6 | 39 | 2 |
| 12/31/2024 | 917 | -29 | 3 | 29 | 2 |
| 6/30/2024 | 912 | -113 | 40 | 49 | N/A |
| 3/31/2024 | 916 | -136 | 26 | 35 | N/A |
| 12/31/2023 | 909 | -168 | -25 | -17 | N/A |
| 9/30/2023 | 901 | -211 | -11 | -1 | N/A |
| 6/30/2023 | 894 | -287 | -29 | -20 | N/A |
| 3/31/2023 | 886 | -331 | -41 | -29 | N/A |
| 12/31/2022 | 712 | -335 | -18 | -7 | N/A |
| 9/30/2022 | 495 | -266 | -38 | -30 | N/A |
| 6/30/2022 | 278 | -151 | -101 | -95 | N/A |
| 3/31/2022 | 64 | -130 | -152 | -147 | N/A |
| 12/31/2021 | 56 | -227 | -160 | -156 | N/A |
| 9/30/2021 | 47 | -228 | -176 | -173 | N/A |
| 6/30/2021 | 46 | -316 | -140 | -137 | N/A |
| 3/31/2021 | 57 | -296 | -80 | -78 | N/A |
| 12/31/2020 | 61 | -200 | -61 | -57 | N/A |
| 9/30/2020 | 62 | -170 | -123 | -101 | N/A |
| 6/30/2020 | 77 | -184 | -157 | -109 | N/A |
| 3/31/2020 | 76 | -164 | -189 | -107 | N/A |
| 12/31/2019 | 64 | -143 | -223 | -113 | N/A |
| 9/30/2019 | 49 | -156 | -200 | -75 | N/A |
| 6/30/2019 | 21 | -84 | -181 | -49 | N/A |
| 3/31/2019 | 1 | -77 | -167 | -49 | N/A |
| 12/31/2018 | N/A | -68 | -122 | -31 | N/A |
| 2/28/2018 | N/A | -13 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VY4 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VY4 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VY4 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VY4's revenue (5.5% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: VY4's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VY4's Return on Equity is forecast to be high in 3 years time